Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphomas, Large-cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, High Grade Lymphomas, Mantle-cell Lymphoma, Lymphoplasmacytic Lymphoma

In brief

This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

Key facts

Study ID

NCT01474681

Run by

Novartis Pharmaceuticals

People needed

27

Starts

2012-01-09

Expected to finish

2016-10-03

Last updated by the study team

2020-12-30

Who can join

Age: 10 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis that qualifies them for a DUCBT
• Absence of recent active mold infection
• Adequate organ function
• Availability of eligible donor material

You may not qualify if…

• Pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used
• Human immunodeficiency virus (HIV) infection
• Active infection
• Extensive prior chemotherapy
• Prior myeloablative allotransplantation or autologous transplant.

Where it is running

• Novartis Investigative Site — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.